These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32258522)

  • 1. Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation.
    Maiwall R; Gupta M
    Transl Gastroenterol Hepatol; 2020; 5():18. PubMed ID: 32258522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.
    Patel YA; Berg CL; Moylan CA
    Dig Dis Sci; 2016 May; 61(5):1406-16. PubMed ID: 26815171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases.
    Han E; Lee YH
    Diabetes Metab J; 2017 Dec; 41(6):430-437. PubMed ID: 29199410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAFLD and liver transplantation: Disease burden, current management and future challenges.
    Burra P; Becchetti C; Germani G
    JHEP Rep; 2020 Dec; 2(6):100192. PubMed ID: 33163950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .
    Samji NS; Heda R; Satapathy SK
    Transl Gastroenterol Hepatol; 2020; 5():10. PubMed ID: 32190778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAFLD and liver transplantation: Current burden and expected challenges.
    Pais R; Barritt AS; Calmus Y; Scatton O; Runge T; Lebray P; Poynard T; Ratziu V; Conti F
    J Hepatol; 2016 Dec; 65(6):1245-1257. PubMed ID: 27486010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease.
    Nagy J; Kovács T
    Physiol Int; 2019 Dec; 106(4):305-310. PubMed ID: 31906711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease.
    Khullar V; Dolganiuc A; Firpi RJ
    World J Transplant; 2014 Jun; 4(2):81-92. PubMed ID: 25032097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.
    Maliakkal BJ
    Transl Gastroenterol Hepatol; 2020; 5():36. PubMed ID: 32632387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?
    Targher G; Chonchol M; Zoppini G; Abaterusso C; Bonora E
    J Hepatol; 2011 May; 54(5):1020-9. PubMed ID: 21145850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances.
    Said A
    World J Gastroenterol; 2013 Dec; 19(48):9146-55. PubMed ID: 24409043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.
    Targher G; Byrne CD
    Nat Rev Nephrol; 2017 May; 13(5):297-310. PubMed ID: 28218263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease.
    El Hadi H; Di Vincenzo A; Vettor R; Rossato M
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
    Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
    Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approach to prevention of non-alcoholic fatty liver disease after liver transplantation.
    Sharma P; Arora A
    Transl Gastroenterol Hepatol; 2020; 5():51. PubMed ID: 33073046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growing challenge of post-liver transplantation non-alcoholic fatty liver disease.
    Kalogirou MS; Giouleme O
    World J Transplant; 2022 Sep; 12(9):281-287. PubMed ID: 36187880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Scorletti E; Byrne CD
    Dig Dis; 2016; 34 Suppl 1():11-8. PubMed ID: 27548822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation.
    Mikolasevic I; Orlic L; Hrstic I; Milic S
    Hepatol Res; 2016 Aug; 46(9):841-52. PubMed ID: 26713425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.